Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 1
1988 1
1991 1
2002 1
2004 1
2017 1
2019 2
2020 5
2021 4
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.
Charlier C, Perrodeau É, Leclercq A, Cazenave B, Pilmis B, Henry B, Lopes A, Maury MM, Moura A, Goffinet F, Dieye HB, Thouvenot P, Ungeheuer MN, Tourdjman M, Goulet V, de Valk H, Lortholary O, Ravaud P, Lecuit M; MONALISA study group. Charlier C, et al. Lancet Infect Dis. 2017 May;17(5):510-519. doi: 10.1016/S1473-3099(16)30521-7. Epub 2017 Jan 28. Lancet Infect Dis. 2017. PMID: 28139432 Free article.
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.
Lambert-Niclot S, Abdi B, Bellet J, Fofana D, De Truchis P, Amat K, Alvarez JC, Surgers L, Allavena C, Zaegell-Faucher O, Morlat P, Palich R, Gibowski S, Costagliola D, Girard PM, Landman R, Assoumou L, Morand-Joubert L; ANRS 170 QUATUOR study group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1510-1521. doi: 10.1093/jac/dkad119. J Antimicrob Chemother. 2023. PMID: 37104815
Sexual transmission of an extensively drug-resistant HIV-1 strain.
Raymond S, Piffaut M, Bigot J, Cazabat M, Montes B, Bertrand K, Martin-Blondel G, Izopet J, Delobel P. Raymond S, et al. Among authors: piffaut m. Lancet HIV. 2020 Aug;7(8):e529-e530. doi: 10.1016/S2352-3018(20)30205-8. Lancet HIV. 2020. PMID: 32763213 No abstract available.
No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy.
Lajaunie R, Cuzin L, Palich R, Makinson A, Bani-Sadr F, Duvivier C, Arvieux C, Rey D, Poizot-Martin I, Delpierre C, Delobel P, Martin-Blondel G; And The Dat’AIDS study group. Lajaunie R, et al. HIV Med. 2022 Mar;23(3):301-306. doi: 10.1111/hiv.13168. Epub 2021 Oct 19. HIV Med. 2022. PMID: 34668293 Free article.
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.
Landman R, de Truchis P, Assoumou L, Lambert S, Bellet J, Amat K, Lefebvre B, Allavena C, Katlama C, Yazdanpanah Y, Molina JM, Petrov-Sanchez V, Gibowski S, Alvarez JC, Leibowitch J, Capeau J, Fellahi S, Duracinsky M, Morand-Joubert L, Costagliola D, Alvarez JC, Girard PM; ANRS 170 QUATUOR study group. Landman R, et al. Lancet HIV. 2022 Feb;9(2):e79-e90. doi: 10.1016/S2352-3018(21)00300-3. Lancet HIV. 2022. PMID: 35120640 Clinical Trial.
24 results